Fubotv earnings beat by $0.10, revenue topped estimates
James Woys, Chief Operating Officer of Molina Healthcare, INC. (NYSE: NYSE:MOH), purchased a total of 10,000 shares of the company’s common stock on August 4, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The purchase comes as the stock trades near its 52-week low of $152.12, with InvestingPro analysis indicating the stock is currently undervalued.
The transactions, both purchases, amounted to a total value of $1,559,365. Woys acquired 5,500 shares at a price of $155.59, with prices ranging from $155.00 to $155.98. Additionally, he purchased 4,500 shares at $156.36, with prices ranging from $156.01 to $156.94. Following these transactions, Woys directly owns 74,331 shares of Molina Healthcare, demonstrating management’s confidence in the company, which maintains strong financials with a P/E ratio of 7.5 and more cash than debt on its balance sheet. For deeper insights into MOH’s valuation and 12+ additional ProTips, visit InvestingPro.
In other recent news, Molina Healthcare reported its second-quarter 2025 earnings, which fell below analyst expectations due to rising medical costs. The company posted adjusted earnings of $5.48 per share, missing the anticipated $5.82 per share, despite a 15% year-over-year increase in revenue to $11.43 billion, which surpassed the consensus estimate of $10.94 billion. The medical care ratio, a critical metric indicating medical costs as a percentage of premium revenue, worsened to 90.4% from 88.6% in the previous year. Additionally, Molina Healthcare has adjusted its full-year guidance downward. In light of these developments, Cantor Fitzgerald downgraded Molina Healthcare from Overweight to Neutral, citing concerns over future margin performance in its Medicaid business. The firm’s price target for Molina was significantly reduced to $210.00 from $312.00. However, Cantor Fitzgerald had previously maintained an Overweight rating with a $312.00 price target following Molina’s revised 2025 guidance, expressing disappointment over management’s earlier clarity issues. These recent developments have brought Molina Healthcare’s financial strategies and future performance into focus for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.